<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04835844</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 20-461</org_study_id>
    <nct_id>NCT04835844</nct_id>
  </id_info>
  <brief_title>RHYTHMIA vs CARTO in Redo Ablation Procedures for Atrial Fibrillation</brief_title>
  <acronym>MAP-AF</acronym>
  <official_title>RHYTHMIA vs CARTO in Redo Ablation Procedures for Atrial Fibrillation: MAP-AF Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MAP-AF study will compare RHYTHMIA vs CARTO in redo ablation of paroxysmal AF with&#xD;
      assessment of both acute procedural profiles and clinical outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary venous conduction recovery is found in most patients undergoing redo ablation&#xD;
      procedures for atrial fibrillation (AF). Identifying gaps in prior ablation lines is&#xD;
      essential to achieve successful outcomes. High density mapping systems have been proposed to&#xD;
      allow the identification of such gaps with speed and accuracy.&#xD;
&#xD;
      The MAP-AF study will compare RHYTHMIA vs CARTO in redo ablation of paroxysmal AF with&#xD;
      assessment of both acute procedural profiles and clinical outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 24, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>System is able to accurately identify gaps</measure>
    <time_frame>At the time of procedure</time_frame>
    <description>Incidence of accurate identification of gaps in prior ablation lines by the system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment success</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Freedom from AF recurrence</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Mapping with CARTO</arm_group_label>
    <description>CARTO (Biosense Webster) in conjunction with CONFIDENSE mapping module and PENTARRAY catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mapping with RHYTHMIA</arm_group_label>
    <description>RHYTHMIA (Boston Scientific) in conjunction with the 64-electrodes ORION mini-basket catheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CARTO</intervention_name>
    <description>Redo-ablation of paroxysmal AF with high density mapping system, CARTO, in conjunction with CONFIDENSE mapping module and PENTARRAY catheter</description>
    <arm_group_label>Mapping with CARTO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RHYTHMIA</intervention_name>
    <description>Redo-ablation of paroxysmal AF with high density mapping system, RHYTHMIA, in conjunction with the 64-electrodes ORION mini-basket catheter.</description>
    <arm_group_label>Mapping with RHYTHMIA</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Electrophysiology clinic patients who are considered candidates for redo paroxysmal AF&#xD;
        ablation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (18-90 years of age) undergoing redo ablation procedures for paroxysmal&#xD;
             AF regardless of the systems or energy sources used during the pre-study ablation&#xD;
             procedure(s).&#xD;
&#xD;
          -  Paroxysmal AF: defined as AF terminating within 7 days of onset either spontaneously&#xD;
             or with electrical or medical cardioversion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persistent AF&#xD;
&#xD;
          -  Prior cardiac surgery&#xD;
&#xD;
          -  Patients with only AFL or AT as the documented recurrent arrhythmia after the&#xD;
             pre-study AF ablation(s).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayman Hussein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ayman Hussein, MD</last_name>
    <phone>216-444-6171</phone>
    <email>husseia@ccf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayman Hussein, MD</last_name>
      <phone>216-444-6171</phone>
      <email>husseia@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Ayman Hussein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>April 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

